Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ash Access Technology, Inc.
Lab results suggest catheter lock has infection-prevention attributes
June 15th, 2005
Ash Access Technology, Inc., revealed more laboratory results, adding anti-biofilm characteristics to previously reported antimicrobial results, thereby further strengthening MethLock's position as a serious contender to replace heparin in a $1 billion market. "We plan to perform more rigorous tests, similar to the extensive tests we did to verify MethLock's antimicrobial attributes, (recently announced), but we are pleased with these first results," explained Roland K. Winger, VP of Engineering and Quality Assurance. "Since biofilm creates a friendly environment to host harmful bacteria associated with catheter-related bloodstream infections...
Source: Physician Law Weekly (2005-06-15)
|
